Immune Cell Decreases Halt Merck’s Dual-Agent Antiretroviral HIV Study

Citing declining lymphocyte and T-cell counts in some patients, Merck has stopped its phase 2 trial of a dual-agent HIV antiretroviral regimen and is probing similar studies for this concerning safety signal.
Source: Drug Industry Daily